CL2014002788A1 - Combinación de anticuerpos anti-mif y los quimioterapeuticos gemcitabina, cisplatina y/o doxorubicina; y su uso contra el cancer. - Google Patents
Combinación de anticuerpos anti-mif y los quimioterapeuticos gemcitabina, cisplatina y/o doxorubicina; y su uso contra el cancer.Info
- Publication number
- CL2014002788A1 CL2014002788A1 CL2014002788A CL2014002788A CL2014002788A1 CL 2014002788 A1 CL2014002788 A1 CL 2014002788A1 CL 2014002788 A CL2014002788 A CL 2014002788A CL 2014002788 A CL2014002788 A CL 2014002788A CL 2014002788 A1 CL2014002788 A1 CL 2014002788A1
- Authority
- CL
- Chile
- Prior art keywords
- chemotherapeutics
- gemcitabine
- cisplatin
- doxorubicin
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Telephonic Communication Services (AREA)
- Data Exchanges In Wide-Area Networks (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261624964P | 2012-04-16 | 2012-04-16 | |
| US201261668932P | 2012-07-06 | 2012-07-06 | |
| US201361778094P | 2013-03-12 | 2013-03-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014002788A1 true CL2014002788A1 (es) | 2015-02-06 |
Family
ID=48625989
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014002788A CL2014002788A1 (es) | 2012-04-16 | 2014-10-16 | Combinación de anticuerpos anti-mif y los quimioterapeuticos gemcitabina, cisplatina y/o doxorubicina; y su uso contra el cancer. |
| CL2016001327A CL2016001327A1 (es) | 2012-04-16 | 2016-05-31 | Terapia de combinación de anticuerpos anti-mif y quimioterapeuticos (divisional de solicitud 2788-14) |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2016001327A CL2016001327A1 (es) | 2012-04-16 | 2016-05-31 | Terapia de combinación de anticuerpos anti-mif y quimioterapeuticos (divisional de solicitud 2788-14) |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20150071942A1 (es) |
| EP (2) | EP2838561A1 (es) |
| JP (2) | JP2015514735A (es) |
| KR (2) | KR20150027048A (es) |
| CN (2) | CN104812411A (es) |
| AU (1) | AU2013202693B2 (es) |
| BR (1) | BR112014025855A8 (es) |
| CA (1) | CA2869990A1 (es) |
| CL (2) | CL2014002788A1 (es) |
| CO (1) | CO7131377A2 (es) |
| HK (1) | HK1206985A1 (es) |
| IL (2) | IL235038A0 (es) |
| MX (1) | MX2014012535A (es) |
| NZ (1) | NZ628363A (es) |
| RU (2) | RU2016117260A (es) |
| WO (1) | WO2013156473A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150029017A (ko) | 2012-07-10 | 2015-03-17 | 박스터 헬쓰케어 에스에이 | 항-mif 면역조직화학 |
| CN106068456A (zh) * | 2014-01-03 | 2016-11-02 | 百深有限责任公司 | 抗‑mif免疫组织化学 |
| EP3277718B1 (en) | 2015-03-31 | 2021-03-24 | Baxalta GmbH | Dosage regimen for anti-mif antibodies |
| US20180155419A1 (en) | 2015-05-18 | 2018-06-07 | Baxalta GmbH | Anti-mif antibodies in the treatment of cancers containing mutant tp53 and/or mutant ras |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6645493B1 (en) | 1993-05-17 | 2003-11-11 | The Picower Institute For Medical Research | Composition containing anti-MIF antibody |
| US6774227B1 (en) * | 1993-05-17 | 2004-08-10 | Cytokine Pharmasciences, Inc. | Therapeutic uses of factors which inhibit or neutralize MIF activity |
| JP4708510B2 (ja) * | 1993-05-17 | 2011-06-22 | サイトカイン ファーマサイエンシズ,インコーポレーテッド | サイトカイン媒介毒性に関係する疾患の治療における遊走阻止因子の抑制 |
| WO2001064749A2 (en) * | 2000-02-28 | 2001-09-07 | Idec Pharmaceuticals Corporation | Method for preparing anti-mif antibodies |
| WO2004062604A2 (en) * | 2003-01-10 | 2004-07-29 | Threshold Pharmaceuticals, Inc. | Treatment of cancer with 2-deoxyglucose |
| US8883160B2 (en) * | 2004-02-13 | 2014-11-11 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) complexes for therapeutic and diagnostic use |
| CA2572318A1 (en) * | 2004-07-02 | 2006-01-12 | Neutec Pharma Plc | Treatment of cancer |
| SG153825A1 (en) * | 2005-12-16 | 2009-07-29 | Ibc Pharmaceuticals Inc | Multivalent immunoglobulin-based bioactive assemblies |
| CN100457895C (zh) * | 2006-05-24 | 2009-02-04 | 中国科学院生物物理研究所 | 鼠抗人巨噬细胞迁移抑制因子单克隆抗体及其应用 |
| US20090220521A1 (en) * | 2008-01-04 | 2009-09-03 | Randolf Kerschbaumer | Anti MIF Antibodies |
| WO2011090492A1 (en) * | 2010-01-19 | 2011-07-28 | Immunomedics, Inc. | Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r) |
| WO2013050457A1 (en) * | 2011-10-07 | 2013-04-11 | Baxter Healthcare S.A. | Characterization of cho-mif gene and protein, and use thereof |
| US9958456B2 (en) * | 2011-10-07 | 2018-05-01 | Baxalta Incorporated | OxMIF as a diagnostic marker |
-
2013
- 2013-04-05 AU AU2013202693A patent/AU2013202693B2/en not_active Ceased
- 2013-04-16 JP JP2015506212A patent/JP2015514735A/ja not_active Withdrawn
- 2013-04-16 EP EP13728681.1A patent/EP2838561A1/en not_active Withdrawn
- 2013-04-16 HK HK15107626.0A patent/HK1206985A1/xx unknown
- 2013-04-16 KR KR1020147031756A patent/KR20150027048A/ko not_active Withdrawn
- 2013-04-16 CN CN201380020353.1A patent/CN104812411A/zh active Pending
- 2013-04-16 RU RU2016117260A patent/RU2016117260A/ru unknown
- 2013-04-16 KR KR1020167010493A patent/KR20160049047A/ko not_active Ceased
- 2013-04-16 US US14/394,711 patent/US20150071942A1/en not_active Abandoned
- 2013-04-16 RU RU2014145887A patent/RU2014145887A/ru not_active Application Discontinuation
- 2013-04-16 MX MX2014012535A patent/MX2014012535A/es unknown
- 2013-04-16 CA CA2869990A patent/CA2869990A1/en not_active Abandoned
- 2013-04-16 CN CN201610283630.3A patent/CN106139143A/zh active Pending
- 2013-04-16 BR BR112014025855A patent/BR112014025855A8/pt not_active IP Right Cessation
- 2013-04-16 WO PCT/EP2013/057894 patent/WO2013156473A1/en not_active Ceased
- 2013-04-16 EP EP16165526.1A patent/EP3064221A1/en not_active Withdrawn
- 2013-04-16 NZ NZ628363A patent/NZ628363A/en not_active IP Right Cessation
-
2014
- 2014-10-07 IL IL235038A patent/IL235038A0/en unknown
- 2014-10-16 CL CL2014002788A patent/CL2014002788A1/es unknown
- 2014-11-13 CO CO14251787A patent/CO7131377A2/es unknown
-
2016
- 2016-04-15 JP JP2016082261A patent/JP2016175918A/ja active Pending
- 2016-05-11 IL IL245604A patent/IL245604A0/en unknown
- 2016-05-31 CL CL2016001327A patent/CL2016001327A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1206985A1 (en) | 2016-01-22 |
| CN104812411A (zh) | 2015-07-29 |
| KR20150027048A (ko) | 2015-03-11 |
| JP2016175918A (ja) | 2016-10-06 |
| CO7131377A2 (es) | 2014-12-01 |
| BR112014025855A2 (es) | 2017-06-20 |
| NZ628363A (en) | 2017-02-24 |
| CN106139143A (zh) | 2016-11-23 |
| JP2015514735A (ja) | 2015-05-21 |
| IL235038A0 (en) | 2014-12-31 |
| KR20160049047A (ko) | 2016-05-04 |
| US20150071942A1 (en) | 2015-03-12 |
| IL245604A0 (en) | 2016-06-30 |
| EP3064221A1 (en) | 2016-09-07 |
| CL2016001327A1 (es) | 2017-01-06 |
| AU2013202693B2 (en) | 2015-01-22 |
| BR112014025855A8 (pt) | 2017-07-25 |
| RU2016117260A3 (es) | 2018-10-23 |
| RU2014145887A (ru) | 2016-06-10 |
| EP2838561A1 (en) | 2015-02-25 |
| MX2014012535A (es) | 2015-04-10 |
| RU2016117260A (ru) | 2018-10-23 |
| WO2013156473A1 (en) | 2013-10-24 |
| AU2013202693A1 (en) | 2013-10-31 |
| CA2869990A1 (en) | 2013-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015023688A2 (pt) | material resistente balístico. | |
| CL2014003294A1 (es) | Derivados de bencimidazol-prolina; y sus usos contra disfunciones orexinergicas. | |
| PL3035936T3 (pl) | Pewne jednostki chemiczne, kompozycje i sposoby | |
| BR112014030278A2 (pt) | anticorpo, e, composição. | |
| CL2014002873A1 (es) | Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer. | |
| BR112015001838A2 (pt) | composições de inibidor de efluxo e métodos de tratamento utilizando o mesmo. | |
| ES2811327T8 (es) | Uso de cannabinoides en el tratamiento de convulsiones atónicas en el síndrome de Lennox-Gastaut | |
| CL2016000777A1 (es) | Biomarcadores de cáncer y usos de los mismos | |
| BR112014030644A2 (pt) | conjunto de projétil de grande volume e componentes múltiplos. | |
| FR3006466B3 (fr) | . | |
| CL2016000685A1 (es) | Material para protección balística, su método de preparación y uso. | |
| BR112013013369A2 (pt) | ligante sigma, uso do mesmo e combinação de pelo menos um ligante sigma | |
| BR112013019327A2 (pt) | composto, e, composição. | |
| BR112014016635A2 (pt) | composto, composição, e, uso de um composto | |
| CL2015001202A1 (es) | Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer. | |
| DK3511004T3 (da) | Kombineret præparat til behandling af cancer | |
| BR112015023620A2 (pt) | preparação de malto-oligossacarídeos. | |
| BR112016011430A2 (pt) | agentes anticâncer e preparação dos mesmos. | |
| DK3052102T3 (da) | Sammensætninger til behandling af cancere | |
| CL2015001458A1 (es) | Composición simbiotica y el uso de la misma. | |
| BR112016002563A2 (pt) | compostos químicos. | |
| CL2014001862A1 (es) | Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia. | |
| CL2014002788A1 (es) | Combinación de anticuerpos anti-mif y los quimioterapeuticos gemcitabina, cisplatina y/o doxorubicina; y su uso contra el cancer. | |
| BR112014032501A2 (pt) | composto, e, composição farmacêutica. | |
| FR3001302B1 (fr) | . |